In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neosil Inc.

Division of Leo Pharma AS
www.neosil.com

Latest From Neosil Inc.

Management appointments at Peplin

Peplinhas named Tom Wiggans chief executive officer. He is currently chairman of Peplin's board of directors and will also continue in that role. Before joining the company, Mr Wiggans served as chairman of the board and CEO of Connetics; he left this role in December 2006 when Connetics was acquired by Stiefel Laboratories. In addition, Peplin has appointed Dr Eugene Bauer president and chief medical officer. Dr Bauer was most recently CEO of Neosil, which has entered into a merger agreement with Peplin.

Companies

Start-Up Previews (11/06)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Moving beyond Accutane and Botox", includes profiles of Magen BioSciences, Neosil, Syntopix and TransDerm. Plus these Start-Ups Across Health Care: Cardiak, Innovive Pharmaceuticals, RHEI Pharmaceuticals and ViewRay.

Neosil Inc.

Neosil Inc. intends to develop NCEs for unmet needs in dermatology. Something of a rarity these days, Neosil intends to become a real pharmaceutical company, taking selected products through regulatory approval to the US market by itself.

Moving Beyond Accutane and Botox

Ever hungry for new investment opportunities, VCs are now backing start-ups developing novel dermatology products for both medical and cosmetic conditions. These aren't your typical "derm" companies. Not content to invent new delivery vectors for existing medicines or reformulate them into more patient friendly creams, these fledgling companies are trying to develop new chemical entities based on novel skin biology.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Leo Pharma AS
  • Senior Management
  • Eugene Bauer, MD, CEO
    Andria Langenberg, MD, VP, Clin. Dev.
  • Contact Info
  • Neosil Inc.
    Phone: (510) 547-3610
    5980 Horton St.
    Ste. 525
    Emeryville, CA 94608
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register